MIST: Rapid drug launch, strong EP adoption, and efficient AFib trial drive growth and financial stability
FDA approval and rapid launch of a new drug have driven positive prescriber and patient feedback, with strong early adoption among electrophysiologists and growing refill rates. The phase III AFib program leverages prior experience, targeting a larger market with operational efficiencies and a soli…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.